✦ LIBER ✦
Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia : A randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor
✍ Scribed by Jorge Cortes; Alfonso Quintás-Cardama; Dan Jones; Farhad Ravandi; Guillermo Garcia-Manero; Srdan Verstovsek; Charles Koller; Jody Hiteshew; Jenny Shan; Susan O'Brien; Hagop Kantarjian
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 230 KB
- Volume
- 117
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.